We want you to feel inspired every day. We are future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you. We are looking for motivated people to work as Biotechnologists who want to make a difference, delivering advanced innovative treatments to patients with unmet needs and join us at one of our facilities. The purpose of the role is manufacturing commercial and clinical grade viral vector batches within a GMP cleanroom facility. Our manufacturing team is a critical part of Oxford Biomedica’s operations. We produce multiple clinical and commercial lentiviral vector-based gene therapy products, across seven cleanroom suites in Oxford. We have opportunities at our Transport Way, Oxbox and Yarnton Facilities. Your responsibilities in this role would be: • Largescale manufacture of ATMPs within GMP cleanroom facilities including: • Upstream adherent and/or suspension mammalian cell culture, transfection and harvest of viral vector products. • Downstream processing including clarification, chromatography, ultra/diafiltration and fill/finish activities. • Ensuring batch success by working using good aseptic techniques. • Preparing, cleaning and maintaining the GMP facility including performing viable and non-viable environmental monitoring. • Preparation of growth media and stock solutions using portable mixing tanks. • Completing Batch Manufacturing Records in a timely fashion throughout the manufacturing process. • Taking part in continuous improvement initiatives & development of production processes. • Investigating quality incidents, deviations and improving procedures. • Working to high standards of health & safety. We are looking for: • BSc Life Sciences or equivalent experience of working within a biological or chemical GMP manufacturing environment. • Prior experience of working within an aseptic environment is advantageous but not essential. • Self-motivated with a strong focus on safety, quality, details, and results. • Good problem solving, interpersonal communication and team skills. • Excellent writing skills and computer literacy. • Flexibility to work shifts. About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • Our values are: Responsible, Responsive, Resilient, Respect • State of the art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you. Collaborate. Contribute. Change lives Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.